Pich Emilio Merlo, Tarnanas Ioannis, Brigidi Patrizia, Collo Ginetta
Gelf Health, Milano, Italy.
Trinity College Dublin, Global Brain Health Institute, Dublin, Ireland.
Neurobiol Stress. 2025 Feb 8;35:100713. doi: 10.1016/j.ynstr.2025.100713. eCollection 2025 Mar.
The Gut Microbiome-Liver-Brain Axis is a relatively novel construct with promising potential to enhance our understanding of Alcohol Use Disorder (AUD), and its therapeutic approaches. Significant alterations in the gut microbiome occur in AUD even before any other systemic signs or symptoms manifest. Prolonged and inappropriate alcohol consumption, by affecting the gut microbiota and gut mucosa permeability, is thought to contribute to the development of behavioral and cognitive impairments, leading to Alcohol-Related Liver Disorders and potentially progressing into alcoholic cirrhosis, which is often associated with severe cognitive impairment related to neurodegeneration, such as hepatic encephalopathy and alcoholic dementia. The critical role of the gut microbiota is further supported by the efficacy of FDA-approved treatments for hepatic encephalopathy in alcoholic cirrhosis (i.e., lactulose and rifaximin). To stimulate new research, we hypothesize that interactions between a maladaptive stress response and a constitutional predisposition to neurodegeneration underlie the progression of AUD to conditions of Alcohol-Related Clinical Concerns with severe cognitive impairment, which represent a significant and costly burden to society. Early identification of AUD individuals at risk for developing these conditions could help to prioritize integrated therapeutic interventions targeting different substrates of the Gut Microbiome-Liver-Brain axis. Specifically, addiction medications, microbiome modulators, stress-reducing interventions, and, possibly soon, novel agents that reduce hepatic steatosis/fibrosis will be discussed in the context of digitally supported integrated therapeutic approaches. The explicit goal of this AUD treatment performed on the early stage of the disorder would be to reduce the transition from AUD to those conditions of Alcohol-Related Common Clinical Concerns associated with severe cognitive impairment, a strategy recommended for most neurological neurodegenerative disorders.
肠道微生物群-肝脏-大脑轴是一个相对较新的概念,具有增强我们对酒精使用障碍(AUD)及其治疗方法理解的潜在前景。即使在出现任何其他全身症状或体征之前,AUD患者的肠道微生物群就会发生显著改变。长期且不适当的饮酒通过影响肠道微生物群和肠道黏膜通透性,被认为会导致行为和认知障碍的发展,进而引发酒精相关性肝病,并可能进展为酒精性肝硬化,而酒精性肝硬化常与神经退行性变相关的严重认知障碍有关,如肝性脑病和酒精性痴呆。FDA批准的治疗酒精性肝硬化肝性脑病的药物(即乳果糖和利福昔明)的疗效进一步支持了肠道微生物群的关键作用。为了激发新的研究,我们假设适应不良的应激反应与神经退行性变的体质易感性之间的相互作用是AUD进展为伴有严重认知障碍的酒精相关临床问题的基础,这些问题给社会带来了重大且昂贵的负担。早期识别有发展为这些疾病风险的AUD个体,有助于优先进行针对肠道微生物群-肝脏-大脑轴不同底物的综合治疗干预。具体而言,将在数字支持的综合治疗方法背景下讨论成瘾药物、微生物群调节剂、减压干预措施,以及可能很快出现的减少肝脂肪变性/纤维化的新型药物。在该疾病早期进行这种AUD治疗的明确目标是减少从AUD转变为与严重认知障碍相关的酒精相关常见临床问题,这是大多数神经退行性疾病推荐的一种策略。